InvestorsHub Logo
Followers 971
Posts 383037
Boards Moderated 6
Alias Born 06/24/2011

Re: None

Tuesday, 10/24/2023 11:33:51 AM

Tuesday, October 24, 2023 11:33:51 AM

Post# of 118379
RGBP plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, RGBP is advancing therapies for treating cancer and autoimmune disorders by modulating the immune checkpoint NR2F6. RGBP is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).
Bullish
Bullish